Try four weeks of The Spectator absolutely free. And for this month only, you'll receive a Spectator wireless phone charger.

Go to www.com.uk forward slash charger.

Hello and welcome to Coronomics, the Spectator series on stories from countries turned upside down by COVID-19.

I'm Kate Andrews. Today's podcast features our panel based around the world, who have selected a story that gives you an inside look at what's happening outside their windows. Sylvia Cerelli-Barelli is reporting from Rome,

and Milan correspondent for the Financial Times. Jennifer Creary is reporting from Hong Kong

and managing editor of the Hong Kong Free Press, and Nick Gillespie is reporting from New York

City, an editor-at-large for Reason

magazine.

This is the sixth and last episode of the first series of Coronomics, but we'll be back

with season two starting the second of June.

If you would like to hear stories and perspectives from a specific country, send your

suggestions and recommendations to podcast at spectator.co.uk.

Sylvia, Jennifer, Nick, thanks for joining me.

I think the stories pick this week really reflect steps forward in tackling the COVID crisis

and also some major setbacks.

I'll start with what's happening here in the UK.

The Sunday Telegraph over the weekend revealed

some really positive news about how blood thinning drugs are now thought to be very helpful in

saving the lives of COVID-19 patients. So London specialists in the medical fields basically made

this breakthrough after discovering that for patients who have very serious cases of coronavirus,

many, if not, most of them seem to be suffering from small blood clots that were filling up in the lungs.

And this does help to explain, maybe even largely explain, why patients end up dying of lung failure

...